Deutsche Bank Upgrades Amedisys to Buy (AMED)

Deutsche Bank is out with a research report this morning, where it upgrades shares of Amedisys Inc. AMED to Buy, from Hold; it has a $39.00 price target on the stock. The DB analysts cited compelling risk/reward to the upside for the upgrade, noting that, while they believe consensus estimates still remain too high for 2011, they see limited downside risk at 4.7x Street-low 2011E EBITDA. On the upside, the analysts added that AMED's fundamentals should stabilize due to recent restructuring efforts, and they believe its shares are poised to recover after having lagged thier coverage universe YTD by 4,900 bps (49%).